¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"malignant melanoma in situ"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
¿µ¹® malignant melanoma ÇÑ±Û ¾Ç¼ºÈæ»öÁ¾
¼³¸í   
  ÇǺο¡¼­ »ý±â´Â ¾ÏÀÇ ÀÏÁ¾. ÁַΠ¹éÀο¡°Ô È£¹ßÇϸç, 50´ë~70´ë¿¡ ¸¹ÀÌ ¹ß»ýÇϰí, ÀþÀº ¿©¼º¿¡°Ô Áõ°¡Çϴ °æÇâÀÌ ÀÖÀ¸¸ç, ÇǺξÏÁß 1~3%¸¦ Â÷ÁöÇϴ µå¹® º´À¸·Î ÇǺο͠±âŸ ±â°üÀÇ ¸á¶ó´Ñ ¼¼Æ÷°è¿¡¼­ À¯·¡Çϴ ¾Ç¼ºÁ¾¾çÀÌ´Ù.
  
  ¿øÀÎÀ¸·Î Àϱ¤³ëÃâ°ú Á÷Á¢ÀûÀΠ°ü°è°¡ ÀÖÀ¸¸ç °¡Á·Àû ¹ß»ýµµ º¼ ¼ö ÀÖ´Ù.
¿µ¹® carcinoma in situ ÇÑ±Û »óÇdz»¾ÏÁ¾
¼³¸í   
  ½ÅüÀÇ ³»ºÎ³ª ¿ÜºÎ¸¦ ½×°í Àִ Á¶Á÷À» »óÇǶó°í ÇÑ´Ù. ÀÌ »óÇÇÀÇ ¾Æ·¡¿¡´Â ´ë°³ »óÇǸ¦ ÁöÁöÇϰí Àִ Á¶Á÷ÀÇ À§¿¡ Á¸ÀçÇÑ´Ù. ±×¸®°í ÀÌ ÁöÁöÁ¶Á÷°ú »óÇÇ »çÀÌ¿¡´Â ±âÀú¸·À̶ó´Â ¸·ÀÌ À־ »óÇǿ͠ÁöÁöÁ¶Á÷À» ±¸ºÐÇØ ÁØ´Ù. ¾ÏÁ¾(carcinoma)¶õ »óÇÇÀÇ ¼¼Æ÷°¡ ¾Ç¼º º¯È­¸¦ ÇÏ¿© »ý±â´Â ¾ÏÀ» ¸»ÇÑ´Ù. Á¦ÀÚ¸®¾ÏÁ¾À̶õ ¾ÏÁ¾ÀÇ ÇÑ Á¾·ù·Î ¾ÏÁ¾ÀÌ ±âÀú¸·À» ¹þ¾î³ªÁö ¸øÇÏ°í »óÇdz» Áï, Á¦ÀÚ¸®¿¡ ¸Ó¹°·¯ Àִ °æ¿ì¸¦ ¸»ÇÑ´Ù.
¿µ¹® malignant tumor ÇÑ±Û ¾Ç¼ºÁ¾¾ç
¼³¸í   
  Á¤»óÀûÀΠÁ¶Á÷ ¼¼Æ÷°¡ °¢Á¾ ¹°¸®Àû-È­ÇÐÀû-»ý¹°ÇÐÀûÀΠ¹ß¾Ï ¹°ÁúÀÇ Àۿ렶Ǵ ¿äÀο¡ ÀÇÇØ µ¹¿¬º¯À̸¦ ÀÏÀ¸ÄѼ­ Çü¼ºµÇ´Â Á¾¾ç. ¹«Á¦ÇÑÀÇ ¼¼Æ÷ºÐ¿­·Î ¸Å¿ì ¿Õ¼ºÇϰԠÁõ½ÄÇÏ¿© ÁÖÀ§Á¶Á÷À» ÆÄ±«-ħ½ÄÇÑ´Ù. ¶Ç ¾î¶² È­Çй°ÁúÀ» ³»¾î ÁÖÀ§ÀÇ Á¶Á÷¼¼Æ÷¸¦ Ä§ÇØÇÒ »Ó¸¸ ¾Æ´Ï¶ó, Ç÷°ü ¹× ¸²ÇÁ°üÀ» µû¶ó ÀüÀÌÇÏ¿© Àü½ÅÀÇ Ä«ÄʽþƸ¦ÀÏÀ¸ÄÑ Á×À½À» ÃÊ·¡ÇÑ´Ù. »óÇǼºÀΠ°ÍÀ» ¾ÏÁ¾À̶ó Çϰí, ºñ»óÇǼºÀΠ°ÍÀ» À°Á¾À̶ó ÇÑ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • choroidal malignant melanoma
    ¸Æ¶ô¸·¾Ç¼ºÈæ»öÁ¾
  • malignant melanoma
    ¾Ç¼ºÈæ»öÁ¾
  • carcinoma in situ
    Á¦ÀÚ¸®¾ÏÁ¾
  • in situ
    Á¦ÀÚ¸®
  • in situ hybridization
    Á¦ÀÚ¸®ºÎÇÕ¹ý, Á¦ÀÚ¸®±³Àâ(¹ý)
  • squamous cell in situ carcinoma
    ÆíÆò¼¼Æ÷Á¦ÀÚ¸®¾ÏÁ¾
  • acral lentiginous melanoma
    ¸»´ÜÈæÀÚÈæ»öÁ¾
  • benign juvenile melanoma
    ¾ç¼º¼Ò¾ÆÈæ»öÁ¾
  • desmoplastic melanoma
    ¼¶À¯Á¶Á÷Çü¼ºÈæ»öÁ¾
  • melanoma
    Èæ»öÁ¾, ¸á¶ó´ÑÁ¾
  • superficial spreading melanoma
    ¾èÀºÈ®»êÈæ»öÁ¾, Ç¥ÀçÈ®»êÈæ»öÁ¾
  • verrucous melanoma
    »ç¸¶±Í¸ð¾çÈæ»öÁ¾
  • malignant
    ¾Ç¼º-
  • malignant anemia
    ¾Ç¼ººóÇ÷
  • malignant carcinoid
    ¾Ç¼ºÄ«¸£½Ã³ëÀ̵å, ¾Ç¼ºÀ¯¾ÏÁ¾
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • malignant melanoma
    ¾Ç¼ºÈæ»öÁ¾
  • melanoma
    Èæ»öÁ¾, ¸á¶ó´ÑÁ¾
  • carcinoma in situ
    »óÇdz»¾ÏÁ¾
  • squamous cell in situ carcinoma
    ÆíÆò¼¼Æ÷»óÇdz»¾ÏÁ¾, ÆíÆò¼¼Æ÷¾ÏÁ¾
  • in situ
    Á¦ÀÚ¸®, Á¤À§Ä¡
  • malignant
    ¾Ç¼º-
  • malignant mesothelioma
    ¾Ç¼ºÁßÇÇÁ¾
  • neuroleptic malignant syndrome
    Ç×Á¤½Åº´¾à¹°¾Ç¼ºÁõÈıº
  • malignant tumor
    ¾Ç¼ºÁ¾¾ç
  • malignant transformation
    ¾Ç¼º¼¼Æ÷Àüȯ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • malignant melanoma
    ¾Ç¼ºÈæ»öÁ¾
  • carcinoma in situ
    »óÇdz»¾ÏÁ¾
  • fluorescent in-situ hybridization
    Çü±¤Á¦ÀÚ¸®ºÎÇÕ¹ý, Çü±¤µ¿¼Ò±³Àâ¹ý
  • in situ hybridization
    Á¦ÀÚ¸®ºÎÇÕ¹ý
  • in situ
    Á¦ÀÚ¸®, Á¤À§Ä¡
  • in situ hybridzation
    Á¦ÀÚ¸®ºÎÇÕÈ­
  • acral lentiginous melanoma
    ¸»´ÜÈæÀÚÈæ»öÁ¾
  • balloon cell melanoma
    dz¼±¼¼Æ÷Èæ»öÁ¾
  • benign juvenile melanoma
    ¾ç¼º¿¬¼ÒÈæ»öÁ¾
  • desmoplastic melanoma
    °áÇÕÁ¶Á÷Çü¼ºÈæ»öÁ¾
  • leptomeningeal melanoma
    ¿¬¼ö¸·Èæ»öÁ¾
  • melanoma
    Èæ»öÁ¾, ¸á¶ó´ÑÁ¾
  • nevocytic melanoma
    ¸ð¹Ý¼¼Æ÷Èæ»öÁ¾
  • nonpigmented melanoma
    ¹«»ö¼ÒÈæ»öÁ¾
  • superficial spreading melanoma
    ¾èÀºÈ®»ê¾Ç¼ºÈæ»öÁ¾
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • acral lentiginous melanoma in situ
    ¿øÀ§Ä¡ ¸»´Ü ÈæÀÚ¼ºÈæ»öÁ¾
  • heritable melanoma syndrome
    À¯Àü¼ºÈæ»öÁ¾ÁõÈıº
  • hybridization, in situ
    Á¦ÀÚ¸®ºÎÇÕ¹ý(ݬùêÛö), µ¿¼ÒºÎÇÕ°áÇÕ
  • in situ
    Á¦ÀÚ¸®ÀÇ
  • in situ
    Á¤À§Ä¡
  • in situ hybridzation
    Á¦ÀÚ¸®ºÎÇÕ¹ý(ݬùêÛö), µ¿¼ÒºÎÇÕ°áÇÕ
  • Hodgkin s disease =malignant lymphoma
    È£ÁîŲº´.
  • Hodgkin s disease =malignant lymphoma
    È£ÁîŲº´.
  • granuloma, malignant
    ¾Ç¼ºÀ°¾ÆÁ¾
  • histiocytoma,malignant fibrous
    Á¶Á÷±¸Á¾, ¾Ç¼º ¼¶À¯¼º
  • histiocytosis,malignant
    ¾Ç¼º
  • hypertension,malignant
    ¾Ç¼º(äÂàõ)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • acral lentiginous melanoma in situ
    ¿øÀ§Ä¡ ¸»´Ü ÈæÀÚ¼ºÈæ»öÁ¾
  • melanoma in situ
    ¿øÀ§Ä¡Èæ»öÁ¾
  • malignant melanoma
    ¾Ç¼ºÈæ»öÁ¾(¡­ýÙßäðþ).
  • malignant melanoma
    ¾Ç¼ºÈæ»öÁ¾(¡­ýÙßäðþ)
  • malignant melanoma
    ¾Ç¼ºÈæ»öÁ¾
  • malignant melanoma
    ¾Ç¼º Èæ»öÁ¾
  • malignant thrombosed melanoma
    ¾Ç¼º Ç÷ÀüÇü¼º Èæ»öÁ¾
  • malignant undifferentiated melanoma
    ¾Ç¼º ¹ÌºÐÈ­ Èæ»öÁ¾
  • metastatic malignant melanoma
    ÀüÀ̼º ¾Ç¼º Èæ»öÁ¾(¡­ç÷àõýÙßäðþ).
  • metastatic malignant melanoma
    ÀüÀ̼º ¾Ç¼º Èæ»öÁ¾(¡­ç÷àõýÙßäðþ)
  • metastatic malignant melanoma
    ÀüÀ̼º ¾Ç¼º Èæ»öÁ¾(¡­ç÷àõýÙßäðþ)
  • breast,carcinoma lobular, in situ
    ¼Ò¿±¼º, ºñħÀ±¼º
  • carcinoma in situ
    »óÇdz»¾ÏÁ¾(ß¾ù«Ò®äßðþ), µ¿¼Ò³»¾ÏÁ¾(ÔÒá¶Ò®äßðþ), ÀνÃÅõ¾ÏÁ¾
  • fluorescence in situ hybridization
  • fluoroscent in-situ hybridization=FISH
    Çü±¤µ¿¼Ò±³Àâ¹ý
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • in situ
    Á¦ÀÚ¸®
  • in situ hybridization
    Á¦ÀÚ¸® Æ¢±â »ý¼º(ßæà÷)
  • in situ hybridization assay
    Á¦ÀÚ¸® Æ¢±â»ý¼º(ßæà÷) ¾Æ½êÀÌ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • melanoma
    Èæ»öÁ¾
  • cancer in situ
    »óÇdz»¾Ï, ÀνÃÅõ¾Ï
  • carcinoma in situ
    »óÇdz»¾ÏÁ¾, µ¿¼Ò³»¾ÏÁ¾, ÀνÃÅõ¾ÏÁ¾
  • in situ
    Á¤»ó¼ÒÀçÀÇ, µ¿¼Ò¹ß»ýºÎÀ§ÀÇ, »ýüÁ¤»óºÎÀ§ÀÇ
  • malignant
    ¾Ç¼ºÀÇ
  • malignant adenoma
    ¾Ç¼º¼±Á¾
  • malignant cachexia
    ¾Ç¼º¾Ç¾×Áú
  • malignant change
    ¾Ç¼ºº¯È­
  • malignant degeneration
    ¾Ç¼ºÈ­
  • malignant granuloma
    ¾Ç¼ºÀ°¾ÆÁ¾
  • malignant hypertension
    ¾Ç¼º°íÇ÷¾ÐÁõ
  • malignant neoplasm
    ¾Ç¼º½Å»ý¹°
  • malignant polyp
    ¾Ç¼ºÆú¸³
  • malignant tumor
    ¾Ç¼ºÁ¾¾ç
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
MM macromolecule; Maelzels metronome; major medical [insurance]; malignant melanoma; manubrium to malle...
MH malignant histiocytosis; malignant hyperpyrexia; malignant hypertension; malignant hyperthermia; mam...
MHS major histocompatibility system; malignant hyperthermia in swine; malignant hyperthermia syndrome; m...
CMM cell-mediated mutagenesis; cutaneous malignant melanoma
HCMM hereditary cutaneous malignant melanoma
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
CMM Cutaneous malignant melanoma
DMM Desmoplastic Malignant Melanoma
MM Malignant Melanoma
MMM Metastatic malignant melanoma
ALM Acral lentiginous melanoma
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • melanoma in situ
    »óÇdz» Èæ»öÁ¾
  • malignant melanoma
    ¾Ç¼º Èæ»öÁ¾
    1. ¿ÜÀ½¿¡ »ý±â´Â °¡Àå Áß¿äÇÑ º´º¯ÀÎ Á¾¾çÀÇ ÀÏÁ¾À¸·Î ¿ÜÀ½ÀÇ ¾Ç¼º Èæ»öÁ¾Àº µå¹°°í, ¿©¼º¿¡¼­ °üÂûµÇ´Â Èæ»öÁ¾ÀÇ 2%°¡ ¿ÜÀ½¿¡¼­ ¹ß»ýÇÑ´Ù. 2. »ö¼Ò ¼¼Æ÷¿¡ »ý±ä ¾Ç¼º Á¾¾ç. 3. Ç¥ÇǼº Èæ»ö±¸¿Í ±× Àü±¸Ã¼·ÎºÎÅÍ ¹ß»ýÇÏ´Â ´ë´ÜÈ÷ ¾Ç¼ºÀÎ Á¾¾çÀÌ´Ù. ¸ðµç ¾Ç¼º Á¾¾ç Áß 1%°¡ ¾Ç¼º Èæ»öÁ¾ÀÌ´Ù. ÀÌÁß 90%´Â ¿ÜÇÇ¿¡ ³ªÅ¸³ª°í 10%´Â ÇǺΠ¿Ü¿¡ ³ªÅ¸³­´Ù. ¸ðµç ¾Ç¼º Èæ»öÁ¾ Áß 1%´Â ±¸°­ ³»¿¡¼­ ¹ß»ýÇÑ´Ù. ¹ß»ýÀ²ÀÌ Áõ°¡µÇ´Â °Íó·³ º¸ÀÌ´Â ÀÌ·± Á¾¾çÀÇ Æ¯È÷ ³ª»Û Á¡Àº ¸²ÇÁ ¼øÈ¯°ú Ç÷¾× ¼øÈ¯À» ÅëÇØ ºü¸£°Ô ÀüÀ̵Ǵ °ÍÀÌ´Ù.
  • carcinoma in situ
    »óÇdz» ¾ÏÁ¾, µ¿¼Ò³» ¾ÏÁ¾, ÀνÃÅõ ¾ÏÁ¾
    ÇÇºÎ¿Í Á¡¸·À» ÀÌȯÇÏ´Â Çü¼º Àå¾Ö¼º »óÇÇ ÁúȯÀ¸·Î¼­ Àü¾Ï º´¼Ò·Î »ý°¢µÇ°í ÀÖ´Ù. °¢È­ ÀÌ»óÁõÀÌ ½ÉÇÏÁö¸¸ ħ¹üÀº µÇÁö ¾ÊÀº »óÅÂÀÌ´Ù.
  • lobular breast carcinoma in situ
    ¼Ò¿±¼º, ºñħÀ±¼º À¯¹æ ¾Ï
  • acral lentiginous melanoma
    ¸»´Ü¼º ÈæÁ¡¾ç Èæ»öÁ¾
    1. »óÇdz» Áõ½ÄÇϰí ÀÖ´Â Á¾¾ç ¼¼Æ÷´Â ¾Ç¼º ÈæÀÚÈæ»öÁ¾°ú À¯»çÇÑ ¼Ò°ßÀ̳ª Ç¥ÇÇ Áõ½Ä°ú ¼öÁö»ó µ¹±â¸¦ Áö´Ñ Èæ»öÁ¾ ¼¼Æ÷µéÀÌ ´Ù¼ö °üÂûµÇ´Â °ÍÀÌ Æ¯Â¡ÀÌ´Ù. 2. ¼±´ÜºÎ »Ó¸¸ ¾Æ´Ï¶ó ¼Õ¹Ù´Ú, ¹ß¹Ù´Ú ÁÖÀ§ ¹× Á¡¸·¿¡µµ »ý±â¸ç ƯÈ÷ µ¿¾çÀο¡°Ô ºóµµ°¡ ³ô´Ù. ºñ±³Àû Àå±â°£ÀÇ ¹ÝÁ¡ ³»Áö´Â ¼ö §¯³ª µÇ´Â ¹Ý ÇüÅ·Π°üÂûµÇ´Â ºñħÀ±±â¸¦ °¡Áö¸ç ƯÈ÷ ¼Õ°¡¶ôÀ̳ª ¹ß°¡¶ô »çÀÌ¿¡ ¹ß»ýÇÏ´Â °æ¿ì¿¡´Â Àå±â°£ ¹ß°ßµÇÁö ¾Ê°í Áö³ª°¡±âµµ ÇÑ´Ù.
  • benign juvenile melanoma
    ¾ç¼º À¯³â¼º Èæ»öÁ¾
    ¾ç¼º, À¶±â¼ºÀÌ¸ç ´Ü´ÜÇϰí ÇÎÅ©»ö ³»Áö ÀÚÀû»öÀ» ¶í ±¸ÁøÀÌ¸ç ´ë°³ ¾à°£ ³«¼³ ¼³Ç¥¸éÀ» °®°í, ÀϹÝÀûÀ¸·Î ¾ó±¼ ƯÈ÷ »´¿¡ ¹ß»ýÇÏ¸ç »çÃá±â Àü¿¡ ¹ßº´ÇÏ´Â °æ¿ì°¡ ¸¹´Ù.
  • early melanoma
    Ãʱâ Èæ»öÁ¾
    ¸á¶ó´Ñ ¼¼Æ÷ÀÇ ¾Ç¼º Á¾¾ç¿¡ Ãʱ⠴ܰè. Á¾Á¾ ¾ç¼º ¸ð¹ÝÀ¸·Î ¿ÀÇØµÈ´Ù. ±¸°­¿¡¼­ °¡Àå ÈçÇÑ Èæ»öÁ¾Àº Ç¥Ãþ È®À强 Èæ»öÁ¾, °áÀý¼º Èæ»öÁ¾, ¸»´ÜÈæ»öÁ¾À¸·Î ³ª´µ¾îÁø´Ù. ¿¹Èİ¡ ³ª»Ú´Ù.
  • early nodular melanoma
    Ãʱ⠼ҰáÀý¼º Èæ»öÁ¾
  • heritable melanoma syndrome
    À¯Àü¼º Èæ»öÁ¾ ÁõÈıº
  • juvenile melanoma
    ¿¬¼Ò¼º Èæ»öÁ¾
  • lentigo maligna melanoma
    ¾Ç¼º Èæ»öÁ¾
    ¸á¶ó´Ñ ¼¼Æ÷¿¡¼­ À¯·¡µÈ ¾Ç¼º Á¾¾ç. ¼öÆò Áõ½Ä±âÀÇ Èæ»öÁ¾ÀÎ ¾à¼º ÈæÀÚÀÇ ¼öÁ÷ Áõ½Ä±â¿¡ ÇØ´çÇÑ´Ù. ¼öÆò Áõ½Ä±âÀÇ Èæ»öÁ¾À¸·Î¼­ Ư¡ÀûÀ¸·Î Á߳⠳»Áö ³ë³âÃþÀÇ ÇÞºµÀ» ¸¹ÀÌ ¹ÞÀº ¾Èº¯ºÎ¿¡ È£¹ßÇÑ´Ù.
  • malignany melanoma
    ¾Ç¼º Èæ»öÁ¾
  • melanoma
    Èæ»öÁ¾
    1. ÇǺγª ´Ù¸¥ ±â°üÀÇ melanocytic system¿¡¼­ »ý±ä Á¾¾ç. ÀÌ ¿ë¾î°¡ ´Üµ¶À¸·Î »ç¿ëµÉ ¶§´Â ¾Ç¼º Èæ»öÁ¾À» ÀÏÄ´´Ù. 2. ÇǺÎÀÇ ¾Ç¼º, ¾îµÎ¿î Âø»ö Á¡ ¶Ç´Â Á¾¾ç. ÇÇºÎ Èæ»öÁ¾ÀÇ 4°¡Áö Á¾·ù´Â Ç¥Àç È®»ê¼º Èæ»öÁ¾, ¾Ç¼º Èæ»öÁ¾, ¸»´Ü Èæ»öÁ¾, °áÀý¼º Èæ»öÁ¾ÀÌ´Ù. À̵é Áß Ã³À½ 3°¡Áö´Â Ç¥À缺À¸·Î ¼ºÀåÇÏ¸ç ¹æ»ç»óÀ¸·Î È®ÀåÇÏ´Â °æÇâÀÌ ÀÖÀ¸¸ç ±íÀÌ Ä§ÅõÇÏÁö´Â ¾Ê´Â´Ù. °áÀý¼º Èæ»öÁ¾Àº ±íÀÌ Ä§ÅõÇϸç ÀüÀ̵ȴÙ. ¾Ç¼º Èæ»öÁ¾Àº 1995³â ¹Ì±¹¿¡¼­ 7,200¸íÀÇ »ç¸Á ¿øÀÎÀ̾ú´Ù.
  • superficially spreading melanoma
    ÆÛÁ®³ª°¡´Â Ç¥À缺 Èæ»öÁ¾
  • borderline malignant epithelial ovarian neoplasms
    °æ°è¼º »óÇǼº ³­¼Ò Á¾¾ç
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
malignant melanoma in situ A melanoma limited to the epidermis and composed of nests of atypical melanocytes and scattered single cells extending into the upper epidermis; local excision is curative although the lesion, if untreated, may soon invade the dermis. Malignant lentigo may be considered a slowly progressive type of malignant melanoma in situ.
(05 Mar 2000)
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
cancer, malignant melanoma A skin cancer that begins in cells called melanocytes that can grow together to form benign (not cancerous) moles. A change in size, shape, or colour of a mole can be a sign of melanoma. Melanoma can be cured if detected early, before spread (metastasis) to other areas of the body. Diagnosis is confirmed with a biopsy of the abnormal skin. Sun exposure can cause skin damage that can lead to melanoma.
(12 Dec 1998)
malignant lentigo melanoma <tumour> A melanoma arising from a malignant lentigo.
(05 Mar 2000)
malignant melanoma <oncology, tumour> A malignant tumour which arises from the pigment producing cells (melanosomes) of the deeper layers of the skin (or the eye). Melanoma is the leading cause of death attributable to skin lesions. Described as an irregular dark skin lesion that may have areas of varying colour. Often greater than 6 mm in diameter.
(27 Sep 1997)
malignant melanoma: gallium imaging <radiology> Greater than50% sensitivity for primary and metastatic sites: 73% sensitivity if lesion is greater than 2 cm, 17% sensitivity if less than 2 cm, see: gallium: indications malignant melanoma
(12 Dec 1998)
malignant melanoma: staging <radiology> Clark staging: level I: all tumour cells above basement membrane (in situ), level II: tumour extends to papillary dermis, level III: tumour extends to interface between papillary and reticular dermis, level IV: tumour extends between bundles of collagen of reticular dermis, level V: tumour invasion of sucutaneous tissue (87% metastases) Breslow staging: thin: less than 0.75 mm depth of invasion, intermediate: 0.76 - 3.99 mm depth of invasion, thick: greater than 4 mm depth of invasion see: malignant melanoma
(12 Dec 1998)
desmoplastic malignant melanoma <tumour> A melanoma with marked fibrosis surrounding atypical spindle-shaped melanocytes in the dermis.
(05 Mar 2000)
adenocarcinoma in situ A noninvasive abnormal proliferation of glands believed to precede the appearance of invasive adenocarcinoma; reported in the endometrium, large intestine, cervix, and other sites.
(05 Mar 2000)
carcinoma in situ Cancer that involves only the cells in which it began and has not spread to other tissues. Lobular carcinoma in situ is found in the lobules of the breast. Ductal carcinoma in situ (also called intraductal carcinoma) arises in the ducts.
(16 Dec 1997)
ductal carcinoma in situ <oncology, tumour> A cancer inside the ducts of breast that has not grown through the wall of the duct into the surrounding tissues. Sometimes referred to as a precancer. Good prognosis is involved with in situ cancers.
(09 Oct 1997)
in situ In the natural or normal place, confined to the site of origin without invasion of neighbouring tissues.
(18 Nov 1997)
in situ hybridisation <molecular biology, technique> Use of a DNA or RNA probe todetect the presence of the complementaryDNA sequence in cloned bacterial or cultured eukaryotic cells.Also used for locating geneson chromosomes. The process is:
Prepare microscope slide with cells in metaphase of mitosis, Treat slide with a weak base. Thus denaturing the DNA. Pour radioactively labelled probe onto the slide. Expose slide to photographic emulsion for a few days or weeks. Develop emulsion.
(13 Oct 1997)
in situ hybridization <molecular biology> The use of a DNA or RNA probe to detect the complementary DNA sequence.
(12 Dec 1998)
in situ nucleic acid hybridization <molecular biology> The use of a DNA or RNA probe to detect the complementary DNA sequence.
(12 Dec 1998)
fluorescence in situ hybridization <molecular biology, technique> A type of in situ hybridization in which target sequences are stained with fluorescent dye so their location and size can be determined using fluorescence microscopy.
This staining is sufficiently distinct that the hybridization signal can be seen both in metaphase spreads and in interphase nuclei.
Acronym: FISH
(25 Jun 1999)
fluorescent in situ hybridization See FISH.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • malignant melanoma
    ¾Ç¼º Èæ»öÁ¾
  • melanoma
    Èæ»öÁ¾
  • malignant
    ¾ÇÀǸ¦ ǰÀº; ¾Ç¼ºÀÇ; ¹ÝÇ×ÀÚ
  • malignant
    À¯ÇØÇÑ;¾Ç¼ºÀÇ;¾ÇÀǸ¦ ǰÀº;... (¿µ»ç) Charles I ½Ã´ëÀÇ ¿Õ´ç¿ø
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á